Temsirolimus in the treatment of relapsed and/or refractory mantle cell lymphoma
Cancer Management and Research, ISSN: 1179-1322, Vol: 2, Issue: 1, Page: 181-189
2010
- 12Citations
- 18Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations12
- Citation Indexes12
- 12
- CrossRef7
- Captures18
- Readers18
- 18
Review Description
Patients with mantle cell lymphoma (MCL) have a poor prognosis; consequently, new therapeutic approaches, such as rapamycin and its derivates, mammalian target of rapamycin (MTOR) inhibitors, are warranted. Temsirolimus (also known as CCI-779), a dihydroester of rapamycin, in MCL cell lines inhibited MTOR, downregulated p21 and v-Raf, and induced autophagy.The first clinical trial in MCL patients was performed using 250 mg of temsirolimus weekly for 6-12 cycles. The overall response rate was 38%; the median time to progression was 6.5 months, median overall survival was 12 months, and the median duration of response was 6.9 months. At lower dose (25 mg/week), the overall response rate was 41%, median overall survival was 14 months, and time to progression was 6 months. In another trial, 162 patients were randomly assigned to receive temsirolimus at 2 different doses (175 mg/week for 3 weeks, then 75 mg or 25 mg/week) or a treatment chosen by the investigator among the most frequently adopted single agents for treatment of relapsed MCL. Patients treated with 175/75 mg of temsirolimus had significantly higher response rates and longer progression-free survival than those treated with investigator's choice therapy. These data support the use of MTOR inhibitors for the treatment of MCL, probably in combination with other agents, such as antiangiogenic drugs or histone acetylase inhibitors. © 2010 Galimberti and Petrini.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=77955407568&origin=inward; http://dx.doi.org/10.2147/cmr.s7960; http://dx.doi.org/10.2147/cmar.s7960; http://www.ncbi.nlm.nih.gov/pubmed/21188109; http://www.dovepress.com/temsirolimus-in-the-treatment-of-relapsed-andor-refractory-mantle-cell-peer-reviewed-article-CMR; http://www.dovepress.com/temsirolimus-in-the-treatment-of-relapsed-andor-refractory-mantle-cell-peer-reviewed-article-CMAR; https://www.dovepress.com/getfile.php?fileID=6615; https://dx.doi.org/10.2147/cmar.s7960; https://www.dovepress.com/temsirolimus-in-the-treatment-of-relapsed-andor-refractory-mantle-cell-peer-reviewed-fulltext-article-CMAR; https://dx.doi.org/10.2147/cmr.s7960
Dove Medical Press Ltd.
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know